According to the latest research report the
transarterial
chemoembolization (TACE) market size is projected to reach USD 15.61
Billion by 2030 at 4.90% CAGR during the forecast period 2022-2030.
Hepatocellular carcinoma (HCC) is a primary
malignancy of the liver and occurs mainly due to chronic liver disease and
cirrhosis. It is the third leading cause of cancer deaths worldwide, with over
500,000 people affected. Transarterial chemoembolization market is the
current standard of therapy for patients with intermediate-stage hepatocellular
carcinoma (HCC). Conventional TACE is considered as a standard treatment for
HCC.
Key Players
Segmentation
By Procedure Type
By Product Type
By End-User
By Region
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Forecast
Registering a CAGR of 8.57%, Transarterial Chemoembolization (TACE) Market is expected to grow from USD 1559.20 Million in 2018 to USD 2777.22 Million by 2025.
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization market is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.
Key Players
Segmentation
By Procedure Type
By Product Type
By Region
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Forecast
Registering a CAGR of 8.57%, Transarterial Chemoembolization (TACE) Market is expected to grow from USD 1559.20 Million in 2018 to USD 2777.22 Million by 2025.
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization market is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.
Key Players
Segmentation
By Procedure Type
By Product Type
By End-User
By Region
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.